Peptide Research

BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice. Its mechanisms of action are multifaceted and have been studied extensively in over 100 animal studies. A central aspect of its activity involves upregulation of growth factor expression, including VEGF (vascular endothelial growth factor), EGF (epidermal growth factor), and their receptors. This pro-angiogenic activity helps explain its remarkable wound-healing and tissue-repair properties observed across multiple tissue types.

BPC-157 also interacts with the nitric oxide (NO) system in a complex, context-dependent manner. It can rescue NO production when it is pathologically inhibited and can attenuate excessive NO when it is overproduced, suggesting a modulatory rather than unidirectional effect. Research by Sikiric et al. has demonstrated that BPC-157 interacts with the dopaminergic system and may counteract both the acute and chronic effects of dopaminergic agents, pointing to direct CNS activity.

At the gastrointestinal level, BPC-157 maintains mucosal integrity by promoting granulation tissue formation and angiogenesis within lesion sites. It has shown cytoprotective effects against NSAID-induced gastric damage, ethanol-induced lesions, and stress ulcers in numerous rodent models. The peptide appears to modulate the FAK-paxillin pathway, which is critical for cell migration and adhesion during wound repair.

Thymosin beta-4 (Tbeta4) is a 43-amino-acid peptide that is the most abundant member of the beta-thymosin family. Despite its name (a historical artifact from its original isolation from thymus tissue), Tbeta4 is expressed in virtually all nucleated cells and is one of the most abundant intracellular peptides, with concentrations reaching 0.4 mM in some cell types. TB-500 is a synthetic version commonly used in research.

The primary intracellular function of Tbeta4 is sequestration of G-actin (globular, monomeric actin), regulating the pool of actin available for polymerization into F-actin (filamentous actin). This function is critical because actin polymerization drives cell migration — a rate-limiting step in wound healing. By maintaining a reserve of polymerization-ready G-actin, Tbeta4 enables rapid cell migration when needed. The active site responsible for actin binding is the central region containing the sequence LKKTET.

Beyond actin regulation, Tbeta4 has potent anti-inflammatory activity. It suppresses NF-kB signaling and reduces pro-inflammatory cytokine expression. Bock-Marquette et al. made a landmark discovery showing Tbeta4 activates Akt (protein kinase B) in cardiomyocytes, promoting survival after ischemic injury. This finding opened research into cardiac repair applications. Tbeta4 also promotes angiogenesis, hair follicle stem cell migration, and has been shown to reduce corneal inflammation and scarring.

GHK-Cu is a naturally occurring copper-binding tripeptide first identified in human plasma by Loren Pickart in 1973. It is found in blood, saliva, and urine, with plasma levels declining from about 200 ng/mL at age 20 to 80 ng/mL by age 60. The copper ion is essential for its biological activity, as it enables the peptide to serve as a bioavailable copper delivery system.

GHK-Cu exerts its biological effects through multiple well-characterized mechanisms. It powerfully stimulates collagen synthesis (types I and III), decorin, and glycosaminoglycan production in dermal fibroblasts. Simultaneously, it upregulates matrix metalloproteinases (MMPs) and their inhibitors (TIMPs), enabling coordinated tissue remodeling rather than simple collagen deposition. This remodeling capacity is key to its wound-healing effects — GHK-Cu promotes organized tissue repair rather than scar formation.

Beyond structural matrix effects, GHK-Cu has potent antioxidant activity via SOD and glutathione pathway upregulation, suppresses inflammatory cytokines including TGF-beta and TNF-alpha, and promotes angiogenesis by inducing VEGF and FGF-2 expression. Gene expression studies by Pickart et al. using the Broad Institute Connectivity Map showed GHK can influence the expression of over 4,000 genes, with patterns suggesting suppression of fibrosis-related and inflammation-related gene networks.

MOTS-c is a 16-amino-acid peptide encoded by the mitochondrial genome within the 12S rRNA gene. Discovered by Changhan David Lee and Pinchas Cohen at the University of Southern California in 2015, it was one of the first mitochondrial-derived peptides (MDPs) identified with significant metabolic regulatory activity. Its discovery challenged the longstanding view that the mitochondrial genome encodes only 13 proteins, 22 tRNAs, and 2 rRNAs.

MOTS-c's primary mechanism involves activation of the AMPK (AMP-activated protein kinase) pathway, the master cellular energy sensor. It inhibits the folate cycle and de novo purine biosynthesis, leading to accumulation of AICAR (an endogenous AMPK activator). This AMPK activation promotes glucose uptake, fatty acid oxidation, and mitochondrial biogenesis — effects that closely mimic the metabolic benefits of exercise. Lee et al. showed that MOTS-c treatment prevented age-dependent and high-fat-diet-induced insulin resistance in mice.

Remarkably, MOTS-c can translocate to the nucleus during metabolic stress, where it regulates nuclear gene expression through interaction with the antioxidant response element (ARE). This represents a novel form of mitochondrial-nuclear communication (retrograde signaling). MOTS-c levels decline with age in human plasma, and exercise has been shown to acutely increase circulating MOTS-c levels, linking it to the molecular mechanisms underlying exercise benefits.

NAD+ is a fundamental coenzyme in cellular energy metabolism, serving as the primary electron carrier in mitochondrial oxidative phosphorylation and as an essential substrate for sirtuins (SIRT1-7), PARPs, and CD38/CD157 enzymes. NAD+ levels decline significantly with age, impairing sirtuin-mediated gene regulation, mitochondrial function, and DNA repair capacity.

The 500mg product contains the same NAD+ compound as the 1000mg biofermented version at a lower quantity. See the NAD 1000mg entry for comprehensive research details on NAD+ biology, the role of NAD+ decline in aging, and the therapeutic potential of NAD+ restoration.